Treeline Biosciences to Acquire Standard Biotools in Reverse Merger

Deal Summary

Treeline Biosciences announced it will acquire Standard Biotools, the rebranded Fluidigm, in a reverse merger. The transaction values Standard at roughly its cash position of about $370 million, giving Treeline a public listing while shedding Standard’s tools portfolio.